Skip to main content

Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

The Original Article was published on 13 May 2020

Correction: Mol Cancer 19, 90 (2020)

https://doi.org/10.1186/s12943-020-01202-9

Following publication of the original article [1], the authors do notice that they mis-claimed the qRT-PCR primers that predicted to target human CDH10 gene as specific primers targeting human BIM gene in Materials and methods section when describing quantitative RT-PCR, and the primers have been mis-used to detect mRNA levels of BIM in Fig. 5d, e and h. They are extremely sorry for the misleading caused by this mistake, and to correctly quantify BIM mRNA levels in their tumor cell models, they have re-designed new specific qRT-PCR primers targeting human BIM (forward primer, 5’-TAAGTTCTGAGTGTGACCGAGA-3’, reverse primer, 5’-GCTCTGTCTGTAGGGAGGTAGG-3’), and repeated the qRT-PCR experiments in Fig. 5d, e and h. As shown below, they observed the similar results as our previous data, which was also consistent with the protein levels of Bim previously determined by immunoblotting in Fig. 5d, e and i. They believe that this mistake could be correct and would not affect their critical conclusions in our published paper. The corrected Fig. 5 and updated data of corrected RT-PCR results are provided below.

Fig. 5
figure 1

Activation of antiapoptotic signaling through the Ack1/AKT pathway contributes to ASK120067 resistance. a The levels of AKT phosphorylation (p-AKT) in NCI-H1975 and 67R cells were determined by immunoblotting analysis. b The inhibitory activity of ASK120067 on p-AKT expression in NCIH1975 cells and 67R cells was compared. c Knockdown of Ack1 expression using short hairpin RNA (shRNA) decreased the levels of phosphorylated AKT in 67R cells. d The mRNA and protein levels of proapoptotic protein BIM in NCI-H1975 and 67R cells were determined by real-time PCR (left panel) and Western blot analysis (right panel), respectively. e The effect of ASK120067 on BIM expression in NCI-H1975 and 67R cells was examined. f Knockdown of Ack1 expression in 67R cells increased the expression of BIM by decreasing the phosphorylation of AKT. g to i, the combination of ASK120067 with Ack1 inhibitors synergistically suppressed AKT activation g and induced the transcription h and protein expression of BIM i

Quantitative RT-PCR

Cells were treated with DMSO or the indicated compounds for 48 h before being subjected to RNA purification via an EZ-press Cell to cDNA Kit (EZBioscience, #B0001). Samples were then analyzed for mRNA expression via qRT-PCR using the iTaq TM Universal SYBR Green Supermix (BioRad, #1725125) and 7500 real-time PCR instrument (Applied Biosystems). The primer sequences were as follows: BIM, forward primer, 5’-TAAGTTCTGAGTGTGACCGAGA-3’, reverse primer, 5’-GCTCTGTCTGTAGGGAGGTAGG-3’; ACTIN, forward primer, 5’-CACCATTGGCAATGAGCGGTTC-3’, reverse primer, 5’-AGGTCTTTGCGGATGTCCACGT-3’. Primer synthesis was completed by TsingkeBiotechnology.

Reference

  1. Zhang T, Qu R, Chan S, et al. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer. 2020;19:90. https://doi.org/10.1186/s12943-020-01202-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Ke Ding, Jian Ding or Hua Xie.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, T., Qu, R., Chan, S. et al. Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer 22, 139 (2023). https://doi.org/10.1186/s12943-023-01842-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12943-023-01842-7